DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+42.82%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$417M
AUM Growth
+$417M
(+30%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$6.14M |
| 2 |
Biohaven
BHVN
|
$5.73M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$3.28M |
| 5 |
Galapagos
GLPG
|
$2.85M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$7.23M |
| 3 |
Cytokinetics
CYTK
|
$6.64M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$4.75M |
| 5 |
Nurix Therapeutics
NRIX
|
$4.38M |
Sector Composition
| 1 | Healthcare | 85.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
MacroGenics
MGNX
$121M
| $1.46M | 0.35% |
152,250
-106,246
| -41% | -$1.02M |
|
|
RGLS
52
DELISTED
Regulus Therapeutics
RGLS
| $1.42M | 0.34% |
1,111,049
| – | – |
|
53
argenx
ARGX
$44.2B
| $1.37M | 0.33% |
+3,600
| New | +$1.37M |
|
54
Gossamer Bio
GOSS
$587M
| $1.35M | 0.32% |
1,476,052
| – | – |
|
55
Cullinan Oncology
CGEM
$456M
| $1.3M | 0.31% |
127,284
| – | – |
|
|
AUTL
56
Autolus Therapeutics
AUTL
$383M
| $1.23M | 0.29% |
191,070
-737,183
| -79% | -$4.75M |
|
57
Sutro Biopharma
STRO
$85.6M
| $1.21M | 0.29% |
283,079
| – | – |
|
58
Immatics
IMTX
$662M
| $1.11M | 0.26% |
+105,000
| New | +$1.11M |
|
|
ITOS
59
DELISTED
iTeos Therapeutics
ITOS
| $1.08M | 0.26% |
98,560
| – | – |
|
60
Neuronetics
STIM
$216M
| $910K | 0.22% |
313,717
| – | – |
|
61
Oric Pharmaceuticals
ORIC
$1.03B
| $670K | 0.16% |
+72,797
| New | +$670K |
|
62
Acrivon Therapeutics
ACRV
$42.2M
| $646K | 0.15% |
131,351
+54,499
| +71% | +$268K |
|
|
NVRO
63
DELISTED
NEVRO CORP.
NVRO
| $603K | 0.14% |
28,000
| – | – |
|
64
Compugen
CGEN
$133M
| $406K | 0.1% |
205,202
| – | – |
|
65
Masimo
MASI
$7.43B
| $352K | 0.08% |
3,000
| – | – |
|
|
ADAP
66
Adaptimmune Therapeutics
ADAP
$13.9M
| $278K | 0.07% |
351,064
| – | – |
|
|
VIGL
67
DELISTED
Vigil Neuroscience
VIGL
| $243K | 0.06% |
71,815
-100,493
| -58% | -$340K |
|
|
ELEV
68
DELISTED
Elevation Oncology
ELEV
| $242K | 0.06% |
450,000
| – | – |
|
69
VistaGen Therapeutics
VTGN
$113M
| $215K | 0.05% |
+41,886
| New | +$215K |
|
70
Spero Therapeutics
SPRO
$117M
| $184K | 0.04% |
125,000
| – | – |
|
71
Compass Therapeutics
CMPX
$466M
| $182K | 0.04% |
116,882
| – | – |
|
72
Karyopharm Therapeutics
KPTI
$61.4M
| $167K | 0.04% |
12,845
| – | – |
|
73
Mineralys Therapeutics
MLYS
$1.94B
| $131K | 0.03% |
+15,200
| New | +$131K |
|
|
KNTE
74
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $119K | 0.03% |
50,000
-55,179
| -52% | -$131K |
|
75
Inogen
INGN
$213M
| $82.4K | 0.02% |
15,000
| – | – |
|